Minimum Age for Mefenamic Acid Initiation
Mefenamic acid can be started at 14 years of age or older, as this is the FDA-approved minimum age for its use in adolescents and adults. 1
FDA-Approved Age Indication
The FDA drug label explicitly states that mefenamic acid is indicated "for relief of mild to moderate pain in patients ≥ 14 years of age" 1. This represents the official regulatory approval for the medication's use in the pediatric population.
Dosing for Adolescents ≥14 Years
For adolescents meeting the minimum age requirement:
- Initial dose: 500 mg as a loading dose
- Maintenance: 250 mg every 6 hours as needed
- Duration: Should not exceed one week for acute pain 1
- For primary dysmenorrhea: Same dosing regimen, typically needed for only 2-3 days 1
Evidence from Clinical Guidelines
Multiple ESMO cancer pain management guidelines consistently list mefenamic acid in their analgesic tables without specific pediatric age restrictions, presenting it as a WHO Level I analgesic with standard adult dosing of capsules 250-500 mg, with a maximum daily dose of 4 × 500 mg 2, 3, 4, 5. However, these guidelines focus on adult cancer pain management and do not provide pediatric-specific recommendations.
Limited Pediatric Research Data
While the FDA approval specifies ≥14 years, some research studies have explored mefenamic acid use in younger children:
- A 2025 observational study evaluated mefenamic acid oral suspension in children as young as 6 months, using weight-based dosing of 5 mg/kg three times daily 6
- A 1977 study examined antipyretic effects in children aged 3 months to 15 years using 4 mg/kg dosing 7
- A 1992 study used mefenamic acid in preterm infants for patent ductus arteriosus at 2 mg/kg/dose 8
However, these research applications do not constitute FDA approval and should not guide routine clinical practice.
Important Safety Considerations
The FDA label specifically notes that "mefenamic acid has not been adequately investigated in pediatric patients less than 14 years of age" 1. A study in preterm infants showed the half-life was approximately five times longer than in adults, consistent with immature metabolic enzyme activity in newborns 1.
Clinical Cautions
When prescribing mefenamic acid to adolescents ≥14 years:
- Use the lowest effective dose for the shortest duration 1
- Monitor for gastrointestinal and renal toxicity, as with all NSAIDs 2, 3
- Avoid in patients with pre-existing renal disease 1
- Consider hepatic function, as metabolism is a significant elimination pathway 1
The clear answer for clinical practice: Do not initiate mefenamic acid in patients younger than 14 years of age outside of research protocols, as this represents off-label use without adequate safety data.